Starling Oncology
STLN· Services· Fiscal year ends in December
No proxy on file names the CEO of Starling Oncology.
Executives3
See all- 1Daniel VirnichFY2025
- 2Yale PodnosFY2025
- 3Robert CarterFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allStarling Oncology paid its 3 named executives $3.4M in total in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| Daniel Virnich | |||
| Yale Podnos | |||
| Robert Carter | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Starling Oncology. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board6
See all- Anne McGeorgeChair · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Mohit KaushalDirector · 5 yr on the boardIndependentCompensation (Chair), Compliance (Chair)—Paid as an executive
- Karen M. JohnsonDirector · 4 yr on the boardIndependentCompliance, Nominating and Corporate Governance (Chair)—Paid as an executive
- Mark PacalaDirector · 3 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Kimberly TzoumakasDirector · -1 yr on the boardIndependentCompliance, Nominating and Corporate Governance—Paid as an executive
- Mark D. StolperDirector · -1 yr on the boardIndependentAudit (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Mar 27, 2025 | FY2024 |
| Annual report | 10-K | Mar 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 2, 2024 | FY2023 |
| Annual report | 10-K | Mar 28, 2024 | FY2023 |
